AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Joule Achieves Industry First With A 100% Increase In Photosynthetic Efficiency

Joule Achieves Industry First With A 100% Increase In Photosynthetic Efficiency

August 15, 2014

Bedford, MA – August 15, 2014 – Overcoming the limitations of photosynthesis, Joule has successfully co-opted nature’s primary energy capture process at unprecedented efficiencies for direct, continuous fuel production. This includes the engineering of a photosynthetic biocatalyst able to divert 95% of fixed carbon normally converted to biomass directly to fuel, and the industry first improvement of its photon energy conversion efficiency.

Allergan Acquires LiRIS® Program from TARIS Biomedical®

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 13, 2014
  • TARIS LiRIS® Program in Phase 2 Clinical Development for the Localized Treatment of Interstitial Cystitis / Bladder Pain Syndrome
  • Acquisition Enhances Allergan’s Leadership Position in Urology and Reinforces the Company’s Commitment to Developing Innovative Treatments to Address Important Medical Needs

Seventh Sense Biosystems Closes $16 Million Series B Financing

Seventh Sense Biosystems Closes $16 Million Series B Financing

August 13, 2014

CAMBRIDGE, Mass., Aug 13, 2014 (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc. (7SBio), the pioneering developer of virtually painless blood collection and diagnostic platforms, today announced a $16 million Series B financing from a syndicate of global leaders in diagnostic technologies, pharmaceuticals and clinical diagnostic laboratory services.

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

Agios Pharmaceuticals Announces the U.S. FDA Grants Fast Track Designation to AG-221 for Treatment of Patients With Acute Myelogenous Leukemia That Harbor an IDH2 Mutation

August 13, 2014

CAMBRIDGE, Mass., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-221 for the treatment of patients with acute myelogenous leukemia (AML) that harbor an isocitrate dehydrogenase-2 (IDH2) mutation. AG-221 is a first-in-class, oral, selective, potent IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies.

Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results

Eleven Biotherapeutics Reports Second Quarter 2014 Financial Results

August 13, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported business highlights and financial results for the second quarter ended June 30, 2014.

Joule to Present Transformative Climate Change Solution at Arendal Week

Joule to Present Transformative Climate Change Solution at Arendal Week

August 12, 2014

Solar conversion of waste CO2 to fuels can simultaneously cut emissions and enable sustainable transportation

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update

August 12, 2014

LEXINGTON, Mass., Aug 12, 2014 (BUSINESS WIRE) -- Concert Pharmaceuticals, Inc.today reported financial results for the second quarter of 2014.

Acceleron Pharma Reports Second Quarter 2014 Financial Results

Acceleron Pharma Reports Second Quarter 2014 Financial Results

August 12, 2014

--Encouraging interim data presented from five phase 2 clinical trials --

-- Two additional phase 2 studies initiated --

-- Pipeline advancement and expansion demonstrate potential value of late-stage clinical opportunities --